JP7217287B2 - アミロイド症の処置および予防 - Google Patents

アミロイド症の処置および予防 Download PDF

Info

Publication number
JP7217287B2
JP7217287B2 JP2020550650A JP2020550650A JP7217287B2 JP 7217287 B2 JP7217287 B2 JP 7217287B2 JP 2020550650 A JP2020550650 A JP 2020550650A JP 2020550650 A JP2020550650 A JP 2020550650A JP 7217287 B2 JP7217287 B2 JP 7217287B2
Authority
JP
Japan
Prior art keywords
antibody
seq
set forth
concentration
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020550650A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019183448A5 (https=
JP2021518393A5 (https=
JP2021518393A (ja
Inventor
タルロチャン ニジャール，
フィリップ ジェイ． ザ サード ドラン，
ロビン バーバー，
Original Assignee
プロシーナ バイオサイエンシーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロシーナ バイオサイエンシーズ リミテッド filed Critical プロシーナ バイオサイエンシーズ リミテッド
Publication of JP2021518393A publication Critical patent/JP2021518393A/ja
Publication of JPWO2019183448A5 publication Critical patent/JPWO2019183448A5/ja
Publication of JP2021518393A5 publication Critical patent/JP2021518393A5/ja
Application granted granted Critical
Publication of JP7217287B2 publication Critical patent/JP7217287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020550650A 2018-03-23 2019-03-22 アミロイド症の処置および予防 Active JP7217287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647341P 2018-03-23 2018-03-23
US62/647,341 2018-03-23
PCT/US2019/023528 WO2019183448A1 (en) 2018-03-23 2019-03-22 Treatment and prophylaxis of amyloidosis

Publications (4)

Publication Number Publication Date
JP2021518393A JP2021518393A (ja) 2021-08-02
JPWO2019183448A5 JPWO2019183448A5 (https=) 2022-03-29
JP2021518393A5 JP2021518393A5 (https=) 2022-03-29
JP7217287B2 true JP7217287B2 (ja) 2023-02-02

Family

ID=66041747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550650A Active JP7217287B2 (ja) 2018-03-23 2019-03-22 アミロイド症の処置および予防

Country Status (13)

Country Link
US (1) US20210017278A1 (https=)
EP (1) EP3768311A1 (https=)
JP (1) JP7217287B2 (https=)
KR (1) KR20200143400A (https=)
CN (1) CN112040983A (https=)
AU (2) AU2019240413A1 (https=)
BR (1) BR112020019172A2 (https=)
CA (1) CA3095100A1 (https=)
EA (1) EA202092264A1 (https=)
MX (1) MX2020009920A (https=)
MY (1) MY203432A (https=)
SG (1) SG11202009295YA (https=)
WO (1) WO2019183448A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510913A (ja) 2007-12-28 2011-04-07 エラン ファーマシューティカルズ，インコーポレイテッド アミロイドーシスの処置および予防
JP2014530917A (ja) 2011-10-25 2014-11-20 オンクレーヴセラピューティクス リミテッド 抗体製剤および方法
WO2018005967A1 (en) 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510913A (ja) 2007-12-28 2011-04-07 エラン ファーマシューティカルズ，インコーポレイテッド アミロイドーシスの処置および予防
JP2014530917A (ja) 2011-10-25 2014-11-20 オンクレーヴセラピューティクス リミテッド 抗体製剤および方法
WO2018005967A1 (en) 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Amyloid，2016年，Vol.23, No.3，p.168-177
PLoS ONE，2012年，Vol.7, No.12，p.e52686

Also Published As

Publication number Publication date
EP3768311A1 (en) 2021-01-27
MY203432A (en) 2024-06-27
CN112040983A (zh) 2020-12-04
CA3095100A1 (en) 2019-09-26
BR112020019172A2 (pt) 2021-01-26
KR20200143400A (ko) 2020-12-23
AU2023202109A1 (en) 2023-05-18
EA202092264A1 (ru) 2020-12-03
WO2019183448A1 (en) 2019-09-26
AU2019240413A1 (en) 2020-10-08
MX2020009920A (es) 2020-12-10
US20210017278A1 (en) 2021-01-21
JP2021518393A (ja) 2021-08-02
SG11202009295YA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
JP2024127990A (ja) アミロイドーシスを処置するための組成物
TW201906866A (zh) 酸性鞘磷脂酶缺乏症患者中異常骨狀況的治療
JP2021526534A5 (https=)
JP7419262B2 (ja) 抗ｐｃｓｋ９抗体を含む製剤およびその使用
JP7687956B2 (ja) 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
KR20220019656A (ko) 경쇄 아밀로이드증 치료 방법
CN111886252A (zh) 促进胰岛细胞生长的方法
JP2018533588A (ja) 治療パラダイム
JP7217287B2 (ja) アミロイド症の処置および予防
KR20230142834A (ko) 항-cd38 항체 및 이의 용도
JP2023502103A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いてループス腎炎を治療する方法
EA044759B1 (ru) Лечение и профилактика амилоидоза
WO2025170969A1 (en) Methods of treating al amyloidosis
CN120019073A (zh) 一种治疗实体瘤的方法
CN120035606A (zh) 一种治疗实体瘤的方法
HK40008815B (en) Compositions for treating amyloidosis
WO2025124481A1 (zh) Tfpi抗体用于治疗血友病
TH2101002581A (th) วิธีการทรีตโรคตาโปนจากไทรอยด์โดยใช้แอนติบอดีชนิด anti-fcrn
CN118076640A (zh) 抗-pla2r自身抗体介导的膜性肾病的治疗
NZ783304A (en) Methods for inhibiting fibrosis in a subject in need thereof
JPWO2021257894A5 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221228

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221228

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230123

R150 Certificate of patent or registration of utility model

Ref document number: 7217287

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150